{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:58:11Z","timestamp":1766023091997,"version":"3.48.0"},"reference-count":49,"publisher":"e-Century Publishing Corporation","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/qciu7322","type":"journal-article","created":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T23:28:45Z","timestamp":1716766125000},"page":"2287-2299","source":"Crossref","is-referenced-by-count":0,"title":["A 35-gene mutation profile predicts the therapeutic outcome of patients with esophageal squamous cell carcinoma receiving neo-adjuvant chemoradiation"],"prefix":"10.62347","volume":"14","author":[{"given":"Wen-Chien","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-249.","journal-title":"CA Cancer J Clin"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1200\/JCO.20.00866","article-title":"Treatment of locally advanced esophageal carcinoma: ASCO guideline","volume":"38","author":"Shah","year":"2020","unstructured":"Shah MA, Kennedy EB, Catenacci DV, Deighton DC, Goodman KA, Malhotra NK, Willett C, Stiles B, Sharma P, Tang L, Wijnhoven BPL and Hofstetter WL. Treatment of locally advanced esophageal carcinoma: ASCO guideline. J Clin Oncol 2020; 38: 2677-2694.","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1200\/JCO.2007.12.9593","article-title":"Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781","volume":"26","author":"Tepper","year":"2008","unstructured":"Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D and Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26: 1086-1092.","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S1470-2045(11)70142-5","article-title":"Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis","volume":"12","author":"KM","year":"2011","unstructured":"Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A and Gebski V; Australasian Gastro-Intestinal Trials Group. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12: 681-692.","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","unstructured":"Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, Ten Kate FJW, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Bilgen EJS, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW and van der Gaast A; CROSS study group. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015; 16: 1090-1098.","journal-title":"Lancet Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ejso.2003.11.009","article-title":"Margin involvement and outcome in oesophageal carcinoma: a 10-year experience in a specialist unit","volume":"30","author":"Mulligan","year":"2004","unstructured":"Mulligan ED, Dunne B, Griffin M, Keeling N and Reynolds JV. Margin involvement and outcome in oesophageal carcinoma: a 10-year experience in a specialist unit. Eur J Surg Oncol 2004; 30: 313-317.","journal-title":"Eur J Surg Oncol"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB Jr, Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A, Martin F, Rice DC, Sarabia AJ, Smythe WR, Vaporciyan AA, Walsh GL and Roth JA. Treatment outcomes of resected esophageal cancer. Ann Surg 2002; 236: 376-84; discussion 384-5.","DOI":"10.1097\/00000658-200209000-00014"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s00268-021-06301-2","article-title":"(Neo)adjuvant chemoradiotherapy is beneficial to the long-term survival of locally advanced esophageal squamous cell carcinoma: a network meta-analysis","volume":"46","author":"Jin","year":"2022","unstructured":"Jin Z, Chen D, Chen M, Wang C, Zhang B, Zhang J, Zhu C and Shen J. (Neo)adjuvant chemoradiotherapy is beneficial to the long-term survival of locally advanced esophageal squamous cell carcinoma: a network meta-analysis. World J Surg 2022; 46: 136-146.","journal-title":"World J Surg"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.21037\/atm-21-3331","article-title":"Pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (NEOCRTEC5010)","volume":"9","author":"Shen","year":"2021","unstructured":"Shen J, Kong M, Yang H, Jin K, Chen Y, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Yang H, Li T, Zhang X, Li Q, Wang G, Mao T, Guo X, Lin T, Liu M, Ma D, Ye M, Wang C, Wang Z, Brunelli A, Cerfolio RJ, D&#x2019;Journo XB, Fernando HC, Lordick F, Fu J, Chen B and Zhu C; written on behalf of the AME Thoracic Surgery Collaborative Group. Pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (NEOCRTEC5010). Ann Transl Med 2021; 9: 1516.","journal-title":"Ann Transl Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1470-2045(05)70288-6","article-title":"Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial","volume":"6","author":"BH","year":"2005","unstructured":"Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET and Denham JW; Trans-Tasman Radiation Oncology Group; Australasian Gastro-Intestinal Trials Group. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005; 6: 659-668.","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1200\/JCO.2013.53.6532","article-title":"Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901","volume":"32","author":"Mariette","year":"2014","unstructured":"Mariette C, Dahan L, Mornex F, Maillard E, Thomas PA, Meunier B, Boige V, Pezet D, Robb WB, Le Brun-Ly V, Bosset JF, Mabrut JY, Triboulet JP, Bedenne L and Seitz JF. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol 2014; 32: 2416-2422.","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1200\/JCO.2001.19.2.305","article-title":"Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma","volume":"19","author":"Urba","year":"2001","unstructured":"Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A and Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001; 19: 305-313.","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"YJ","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J and Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3390\/cancers14061522","article-title":"Toward targeted therapies in oesophageal cancers: an overview","volume":"14","author":"Bregni","year":"2022","unstructured":"Bregni G and Beck B. Toward targeted therapies in oesophageal cancers: an overview. Cancers (Basel) 2022; 14: 1522.","journal-title":"Cancers (Basel)"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.7150\/jca.12346","article-title":"Predicting the response of neoadjuvant therapy for patients with esophageal carcinoma: an in-depth literature review","volume":"6","author":"Tao","year":"2015","unstructured":"Tao CJ, Lin G, Xu YP and Mao WM. Predicting the response of neoadjuvant therapy for patients with esophageal carcinoma: an in-depth literature review. J Cancer 2015; 6: 1179-1186.","journal-title":"J Cancer"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000443607","article-title":"Novel candidate biomarkers of chemoradiosensitivity in esophageal squamous cell carcinoma: a systematic review","volume":"56","author":"Sato","year":"2016","unstructured":"Sato Y, Motoyama S, Saito H and Minamiya Y. Novel candidate biomarkers of chemoradiosensitivity in esophageal squamous cell carcinoma: a systematic review. Eur Surg Res 2016; 56: 141-153.","journal-title":"Eur Surg Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.3748\/wjg.v22.i7.2284","article-title":"Genomic characterization of esophageal squamous cell carcinoma: insights from next-generation sequencing","volume":"22","author":"Sasaki","year":"2016","unstructured":"Sasaki Y, Tamura M, Koyama R, Nakagaki T, Adachi Y and Tokino T. Genomic characterization of esophageal squamous cell carcinoma: insights from next-generation sequencing. World J Gastroenterol 2016; 22: 2284-2293.","journal-title":"World J Gastroenterol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"729418","DOI":"10.3389\/fonc.2021.729418","article-title":"Combination of 35-gene mutation profile and radiotherapy dosimetry predicts the therapeutic outcome of definitive chemoradiation in patients with esophageal squamous cell carcinoma","volume":"11","author":"Tang","year":"2021","unstructured":"Tang P, Tan C, Pang Q, Chi CW, Wang Y, Yuan Z, Huang YC and Chen YJ. Combination of 35-gene mutation profile and radiotherapy dosimetry predicts the therapeutic outcome of definitive chemoradiation in patients with esophageal squamous cell carcinoma. Front Oncol 2021; 11: 729418.","journal-title":"Front Oncol"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Dreyer CA, VanderVorst K, Free S, Rowson-Hodel A and Carraway KL. The role of membrane mucin MUC4 in breast cancer metastasis. Endocr Relat Cancer 2021; 29: R17-R32.","DOI":"10.1530\/ERC-21-0083"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1097\/JTO.0b013e3181ec173d","article-title":"Receiver operating characteristic curve in diagnostic test assessment","volume":"5","author":"Mandrekar","year":"2010","unstructured":"Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol 2010; 5: 1315-1316.","journal-title":"J Thorac Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"558","DOI":"10.4097\/kja.19087","article-title":"Multicollinearity and misleading statistical results","volume":"72","author":"Kim","year":"2019","unstructured":"Kim JH. Multicollinearity and misleading statistical results. Korean J Anesthesiol 2019; 72: 558-569.","journal-title":"Korean J Anesthesiol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"5062","DOI":"10.1200\/JCO.2009.22.2083","article-title":"Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer","volume":"27","author":"Allum","year":"2009","unstructured":"Allum WH, Stenning SP, Bancewicz J, Clark PI and Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009; 27: 5062-5067.","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0140-6736(12)60643-6","article-title":"Oesophageal carcinoma","volume":"381","author":"Pennathur","year":"2013","unstructured":"Pennathur A, Gibson MK, Jobe BA and Luketich JD. Oesophageal carcinoma. Lancet 2013; 381: 400-412.","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Puhr HC, Preusser M and Ilhan-Mutlu A. Immunotherapy for esophageal cancers: what is practice changing in 2021? Cancers (Basel) 2021; 13: 4632.","DOI":"10.3390\/cancers13184632"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I and Kitagawa Y; CheckMate 648 Trial Investigators. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med 2022; 386: 449-462.","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"JM","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, Cho BC, Mansoor W, Li SH, Sunpaweravong P, Maqueda MA, Goekkurt E, Hara H, Antunes L, Fountzilas C, Tsuji A, Oliden VC, Liu Q, Shah S, Bhagia P and Kato K; KEYNOTE-590 Investigators. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 2021; 398: 759-771.","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1017\/S0016672309990164","article-title":"Relative mutation rates of each nucleotide for another estimated from allele frequency spectra at human gene loci","volume":"91","author":"Park","year":"2009","unstructured":"Park L. Relative mutation rates of each nucleotide for another estimated from allele frequency spectra at human gene loci. Genet Res (Camb) 2009; 91: 293-303.","journal-title":"Genet Res (Camb)"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40246-015-0056-9","article-title":"Integrative genomic analysis reveals functional diversification of APOBEC gene family in breast cancer","volume":"9","author":"Zhang","year":"2015","unstructured":"Zhang Y, Delahanty R, Guo X, Zheng W and Long J. Integrative genomic analysis reveals functional diversification of APOBEC gene family in breast cancer. Hum Genomics 2015; 9: 34.","journal-title":"Hum Genomics"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S1383-5742(00)00031-4","article-title":"Thymine-DNA glycosylase and G to A transition mutations at CpG sites","volume":"462","author":"Waters","year":"2000","unstructured":"Waters TR and Swann PF. Thymine-DNA glycosylase and G to A transition mutations at CpG sites. Mutat Res 2000; 462: 137-147.","journal-title":"Mutat Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/nrc2761","article-title":"Mucins in cancer: function, prognosis and therapy","volume":"9","author":"Kufe","year":"2009","unstructured":"Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009; 9: 874-885.","journal-title":"Nat Rev Cancer"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"14147","DOI":"10.18632\/oncotarget.13122","article-title":"Cell membraneanchored MUC4 promotes tumorigenicity in epithelial carcinomas","volume":"8","author":"Xia","year":"2017","unstructured":"Xia P, Choi AH, Deng Z, Yang Y, Zhao J, Wang Y, Hardwidge PR and Zhu G. Cell membraneanchored MUC4 promotes tumorigenicity in epithelial carcinomas. Oncotarget 2017; 8: 14147-14157.","journal-title":"Oncotarget"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.2217\/fon.09.125","article-title":"Muc4\/MUC4 functions and regulation in cancer","volume":"5","author":"Carraway","year":"2009","unstructured":"Carraway KL, Theodoropoulos G, Kozloski GA and Carothers Carraway CA. Muc4\/MUC4 functions and regulation in cancer. Future Oncol 2009; 5: 1631-1640.","journal-title":"Future Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13046-019-1279-8","article-title":"Mucin 17 inhibits the progression of human gastric cancer by limiting inflammatory responses through a MYH9-p53-RhoA regulatory feedback loop","volume":"38","author":"Yang","year":"2019","unstructured":"Yang B, Wu A, Hu Y, Tao C, Wang JM, Lu Y and Xing R. Mucin 17 inhibits the progression of human gastric cancer by limiting inflammatory responses through a MYH9-p53-RhoA regulatory feedback loop. J Exp Clin Cancer Res 2019; 38: 283.","journal-title":"J Exp Clin Cancer Res"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"800679","DOI":"10.3389\/fmolb.2021.800679","article-title":"Somatic mutation profiles revealed by next generation sequencing (NGS) in 39 Chinese hepatocellular carcinoma patients","volume":"8","author":"Ke","year":"2022","unstructured":"Ke L, Shen J, Feng J, Chen J, Shen S, Li S, Kuang M, Liang L, Lu C, Li D, He Q, Peng B and Hua Y. Somatic mutation profiles revealed by next generation sequencing (NGS) in 39 Chinese hepatocellular carcinoma patients. Front Mol Biosci 2022; 8: 800679.","journal-title":"Front Mol Biosci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.tibs.2009.10.003","article-title":"Mucin-interacting proteins: from function to therapeutics","volume":"35","author":"Senapati","year":"2010","unstructured":"Senapati S, Das S and Batra SK. Mucin-interacting proteins: from function to therapeutics. Trends Biochem Sci 2010; 35: 236-245.","journal-title":"Trends Biochem Sci"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"16209","DOI":"10.1073\/pnas.0705984104","article-title":"Gel-forming mucins appeared early in metazoan evolution","volume":"104","author":"Lang","year":"2007","unstructured":"Lang T, Hansson GC and Samuelsson T. Gel-forming mucins appeared early in metazoan evolution. Proc Natl Acad Sci U S A 2007; 104: 16209-16214.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"6060","DOI":"10.1073\/pnas.84.17.6060","article-title":"Cloning of partial cDNA encoding differentiation and tumor-associated mucin glycoproteins expressed by human mammary epithelium","volume":"84","author":"Gendler","year":"1987","unstructured":"Gendler SJ, Burchell JM, Duhig T, Lamport D, White R, Parker M and Taylor-Papadimitriou J. Cloning of partial cDNA encoding differentiation and tumor-associated mucin glycoproteins expressed by human mammary epithelium. Proc Natl Acad Sci U S A 1987; 84: 6060-6064.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"9458","DOI":"10.1021\/ja072181b","article-title":"Serine versus threonine glycosylation: the methyl group causes a drastic alteration on the carbohydrate orientation and on the surrounding water shell","volume":"129","author":"Corzana","year":"2007","unstructured":"Corzana F, Busto JH, Jimenez-Oses G, Garcia de Luis M, Asensio JL, Jimenez-Barbero J, Peregrina JM and Avenoza A. Serine versus threonine glycosylation: the methyl group causes a drastic alteration on the carbohydrate orientation and on the surrounding water shell. J Am Chem Soc 2007; 129: 9458-9467.","journal-title":"J Am Chem Soc"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1177\/00220345930720120401","article-title":"A comparison of serine and threonine O-glycosylation by UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase","volume":"72","author":"O&#x2019","year":"1993","unstructured":"O&#x2019;Connell BC and Tabak LA. A comparison of serine and threonine O-glycosylation by UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase. J Dent Res 1993; 72: 1554-1558.","journal-title":"J Dent Res"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"16884","DOI":"10.1074\/jbc.272.27.16884","article-title":"Discovery of the shortest sequence motif for high level mucin-type O-glycosylation","volume":"272","author":"Yoshida","year":"1997","unstructured":"Yoshida A, Suzuki M, Ikenaga H and Takeuchi M. Discovery of the shortest sequence motif for high level mucin-type O-glycosylation. J Biol Chem 1997; 272: 16884-16888.","journal-title":"J Biol Chem"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/nrm2203","article-title":"Mechanisms of specificity in protein phosphorylation","volume":"8","author":"Ubersax","year":"2007","unstructured":"Ubersax JA and Ferrell JE Jr. Mechanisms of specificity in protein phosphorylation. Nat Rev Mol Cell Biol 2007; 8: 530-541.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"6921","DOI":"10.1074\/jbc.R112.418558","article-title":"Mucin-type O-glycosylation during development","volume":"288","author":"Tran","year":"2013","unstructured":"Tran DT and Ten Hagen KG. Mucin-type O-glycosylation during development. J Biol Chem 2013; 288: 6921-6929.","journal-title":"J Biol Chem"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1006\/jmbi.1999.3310","article-title":"Sequence and structure-based prediction of eukaryotic protein phosphorylation sites","volume":"294","author":"Blom","year":"1999","unstructured":"Blom N, Gammeltoft S and Brunak S. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J Mol Biol 1999; 294: 1351-1362.","journal-title":"J Mol Biol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1038\/emboj.2013.79","article-title":"Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology","volume":"32","author":"Steentoft","year":"2013","unstructured":"Steentoft C, Vakhrushev SY, Joshi HJ, Kong Y, Vester-Christensen MB, Schjoldager KT, Lavrsen K, Dabelsteen S, Pedersen NB, Marcos-Silva L, Gupta R, Bennett EP, Mandel U, Brunak S, Wandall HH, Levery SB and Clausen H. Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology. EMBO J 2013; 32: 1478-1488.","journal-title":"EMBO J"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"832","DOI":"10.7150\/ijbs.75963","article-title":"Acquired resistance to EGFR-TKIs in NSCLC mediates epigenetic downregulation of MUC17 by facilitating NF-kappaB activity via UHRF1\/DNMT1 complex","volume":"19","author":"Lin","year":"2023","unstructured":"Lin S, Ruan H, Qin L, Zhao C, Gu M, Wang Z, Liu B, Wang H and Wang J. Acquired resistance to EGFR-TKIs in NSCLC mediates epigenetic downregulation of MUC17 by facilitating NF-kappaB activity via UHRF1\/DNMT1 complex. Int J Biol Sci 2023; 19: 832-851.","journal-title":"Int J Biol Sci"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1002\/j.1460-2075.1996.tb00822.x","article-title":"Myosin heavy chain isoforms regulate muscle function but not myofibril assembly","volume":"15","author":"Wells","year":"1996","unstructured":"Wells L, Edwards KA and Bernstein SI. Myosin heavy chain isoforms regulate muscle function but not myofibril assembly. EMBO J 1996; 15: 4454-4459.","journal-title":"EMBO J"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"772701","DOI":"10.3389\/fcell.2022.772701","article-title":"Identification of the immune signatures for ovarian cancer based on the tumor immune microenvironment genes","volume":"10","author":"Shen","year":"2022","unstructured":"Shen X, Gu X, Ma R, Li X and Wang J. Identification of the immune signatures for ovarian cancer based on the tumor immune microenvironment genes. Front Cell Dev Biol 2022; 10: 772701.","journal-title":"Front Cell Dev Biol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/j.bbadis.2017.11.018","article-title":"Prediction of potential drivers connecting different dysfunctional levels in lung adenocarcinoma via a protein-protein interaction network","volume":"1864","author":"Yuan","year":"2018","unstructured":"Yuan F and Lu W. Prediction of potential drivers connecting different dysfunctional levels in lung adenocarcinoma via a protein-protein interaction network. Biochim Biophys Acta Mol Basis Dis 2018; 1864: 2284-2293.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.7150\/jca.51806","article-title":"The genetic effect and molecular function of the SOCS5 in the prognosis of esophageal squamous cell carcinoma","volume":"12","author":"Yang","year":"2021","unstructured":"Yang PW, Chang YH, Wong LF, Lin CC, Huang PM, Hsieh MS and Lee JM. The genetic effect and molecular function of the SOCS5 in the prognosis of esophageal squamous cell carcinoma. J Cancer 2021; 12: 2216-2229.","journal-title":"J Cancer"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/5\/ajcr0155326.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:53:28Z","timestamp":1766022808000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/5\/ajcr0155326.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":49,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/qciu7322","relation":{},"ISSN":["2156-6976"],"issn-type":[{"type":"electronic","value":"2156-6976"}],"subject":[],"published":{"date-parts":[[2024]]}}}